miércoles, 1 de junio de 2016

Cancer Information Highlights

Cancer Information Highlights

National Cancer Institute

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
New from NCI
Drs. Yarchoan and Uldrick Clinical Trial for HIV-Positive Cancer Patients

People with HIV are living longer and many are now developing cancers linked with older age. NCI researchers are testing the safety of pembrolizumab in HIV-positive patients with cancer that has come back or not responded to previous treatment. Pembrolizumab is an immune therapy drug.
tumor conjugate receptor Moles to Melanoma: Recognizing the ABCDE Features

This website uses a series of photographs to help people see how common moles, dysplastic nevi, and melanomas are different. Each series of images is described with its ABCDE features: asymmetry, border, color, diameter (size), and evolving, or changing over time.
Use of PET-CT Scans May Reduce Need for Surgery for Head and Neck Cancer

A recent study compared two groups of patients with advanced head and neck cancer. Patients who were monitored with PET-CT scans had fewer operations but similar overall survival rates compared with patients who had neck dissection surgery.
PDQ on tablet Cervical Cancer Treatment

We’ve revised our PDQ summary to include more up-to-date information on risk factors for cervical cancer.
Pharmacist looking at vial New Drug for Bladder Cancer

We’ve added a drug summary about atezolizumab. The Food and Drug Administration (FDA) recently approved it to treat urothelial carcinoma, which is a type of bladder cancer.
Nivolumab for Hodgkin Lymphoma

We've updated our drug summary on nivolumab. Nivolumab is now approved by the FDA to treat classical Hodgkin lymphoma in certain patients who have had a stem cell transplant.
Lenvatinib for Kidney Cancer

Our drug summary on lenvatinib mesylate has been updated to include the recent approval from the FDA. Lenvatinib mesylate is now approved to treat renal cell carcinoma, the most common form of kidney cancer.
Cabozantinib for Kidney Cancer

The Cabometyx brand of cabozantinib-s-malate was recently approved by the FDA to treat renal cell carcinoma. We've updated our drug summary on cabozantinib-s-malate to include this recent approval.
Also of Interest

June 5 is National Cancer Survivors Day. Many survivors say that they felt they had lots of support during their treatment, but once it ended it was hard to make a transition to a new way of life. Learn about survivorship after cancer treatment, how to plan for follow-up care, and the physical, emotional, and family issues you may face after treatment.
Prostate Cancer

June is Men’s Health Month. Visit our prostate cancer gateway page to learn about prostate cancer treatment, prevention, genetics, causes, screening, clinical trials, research, and statistics.
Long Distance Caregiving

Even if you live far away from a loved one with cancer, it's possible for you to give support and help solve problems and coordinate care. Find information about managing the needs of long distance caregivers.

No hay comentarios:

Publicar un comentario